Failure Is Not an Option — Understanding CCM^®  Therapy

This program will introduce CCM^® therapy as an option for treating NYHA Stage III Heart Failure patients that remain symptomatic despite being on optimal medical treatment. The faculty will explain and break down the mechanism of action of cardiac contractility modulation. The faculty will discuss the screening process for eligible CCM patients from the EP and HF clinical workflow perspectives. Utilizing their personal experience, our thought leaders will explore and describe their experience with CCM and illustrate real-life patient responses to the therapy. The session will also offer case studies to demonstrate processes and outcomes. Lastly, we will allow time for questions and answers to encourage participation and foster a valuable discussion.

Learning Objectives

• Recognize the indications for CCM therapy 
• Discuss the current treatment regimen for Stage III NYHA HF options to date 
• Gain screening techniques for CCM therapy and determine patient eligibility 
• Learn how to present CCM to patients, including those with an existing device 
• Explain patient benefits associated with CCM therapy

MODERATOR

FACULTY